Scottsdale, Ariz.-based East Valley Urology has completed the first three prostate cancer procedures in PROCEPT BioRobotics’ FDA-approved WATER IV trial using Aquablation therapy. The outpatient procedures, performed by Rahul Mehan, MD, were completed without complications and with same-day discharge, according to a July 23 press release.
The trial compares Aquablation therapy — a robotically controlled waterjet procedure — to radical prostatectomy in men with localized prostate cancer (grade group 1 to 3). The milestone demonstrates the potential for treating prostate cancer in a more scalable, cost-effective outpatient setting, according to the release.
Aquablation aims to offer a middle-ground approach by removing most of the prostate and diagnosed cancer while potentially preserving function. The trial results are pending.
